Imagine what medicine can be™
Imagine what medicine can be.
Targeting key functional cognitive networks in neurological processes relevant to disease.
Targeting key functional cognitive networks in neurological processes relevant to disease.
**Selective Stimulus Management**


- Worldwide exclusive license from UCSF for all technologies deploying interference processing stimulus

- Major disorders suffer from inability to process, filter & respond to competing stimuli

- Key Functional Dependency: Attention, Working Memory & Executive Function

- Core Technologies: Proprietary proprietary mechanisms targeting key neurobiological processing systems

- Patent-pending, proprietary technologies targeting key neurobiological processing systems
Adaptive, Autonomous, Closed-Loop System
Adaptive digital medicine leveraging consumer-grade video game mechanics...
<table>
<thead>
<tr>
<th>Condition</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy</td>
<td></td>
</tr>
<tr>
<td>Major Depression</td>
<td></td>
</tr>
<tr>
<td>Multiple Sclerosis</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Parkinson's Disease</td>
<td></td>
</tr>
<tr>
<td>Traumatic Brain Injury</td>
<td></td>
</tr>
<tr>
<td>Prodromal Alzheimer's</td>
<td></td>
</tr>
<tr>
<td>Multiple MSclerosis</td>
<td></td>
</tr>
<tr>
<td>Major Depression</td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td></td>
</tr>
<tr>
<td>ADHD (Pediatric)</td>
<td>Treatment</td>
</tr>
<tr>
<td>Pediatric</td>
<td></td>
</tr>
<tr>
<td>Autism Spectrum Disorder</td>
<td></td>
</tr>
<tr>
<td>Sensory Processing Disorder</td>
<td></td>
</tr>
</tbody>
</table>

**Population Status**

**Collaborators**

**Clinical Trials using Akili Products**
Sample of public trial results

Published Akili Data
Developing groundbreaking science to transform neurological medicine

From Science to Products
<table>
<thead>
<tr>
<th>Partnerships</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Akili</strong></td>
<td><em>Pediatric autism + ADHD</em>&lt;br&gt;Philanthropic investment (through DELSIA)</td>
</tr>
<tr>
<td><strong>Amgen</strong></td>
<td>Direct investment in Akili’s Series B financing</td>
</tr>
<tr>
<td><strong>Merck Ventures</strong></td>
<td>Direct investment in Akili’s Series B financing</td>
</tr>
<tr>
<td><strong>Shire</strong></td>
<td>ADHD efficacy trial&lt;br&gt;and collaboration on Akili’s first pediatric efficacy trial&lt;br&gt;Direct investment in Akili’s Series A financing</td>
</tr>
<tr>
<td><strong>Pfizer</strong></td>
<td>Prodromal Alzheimer’s disease&lt;br&gt;Non-exclusive R&amp;D collaboration on clinical trial for Akili’s Screen as a digital biomarker</td>
</tr>
</tbody>
</table>
Adapтиве digital medicine leveraging consumer-grade video game mechanics...

Akiili’s Product Lines

Monitors

Configurable regimen

Cognitive tracker

Highly sensitive evaluation

For clinical research

Accessible, safe intervention

Doctor prescribed,

Treatments
A new component in the care paradigm. Fitting within, and extending beyond.

Akili’s Products

- Prescription treatments for disorders with unmet needs associated with debilitating cognitive deficiency
- Warm relationships with patients and physicians to deliver dedicated services and support
- Integrated healthcare solution apps connect patients and physicians for rich meaningful discussions based on objective data owned by akili
- Real medical option prescribed by physicians
- Monthly treatment and data access
- virect relationship with patients or caregivers
- Integrated measurement
- 8 caregivers

Copyright © 2018, Akili Interactive Labs, Inc.

PROPRIETARY
Adapтиве digital medicine leveraging consumer-grade video game mechanics...
Demonstrates the power of Project EVO measurements to discriminate children with neurodevelopmental disabilities, while standard cognitive tests cannot.

- Navigation multi-task threshold targeting 
  - Cohorts not statistically different
  - Specificity has 87% sensitivity and 75% specificity
  - Targeting threshold, and reaction time

More Sensitive Than Standard Test
Current Screening Paradigm

EVO® Screening Paradigm

Opportunity

Drug prescription

Confirmation PET/CSF

Pre-screening

Periodic / low burden

No periodic screening options for long term monitoring for periodic screening options

Copyright © 2018, Akili Interactive Labs, Inc.

PROPRIETARY
**Primary Endpoint**

The effect of cognitive metrics from Project EVO to discriminate between amyloid and amyloid - healthy elderly multi groups

**Secondary Endpoint**

Improvement in attention, impulsivity, and memory measures between pre- and post-intervention amyloid and non-amyloid cohorts on attention and memory pre- and post-intervention

**Exploratory Endpoints**

Effect of drug on attention and memory

**Subject**

- N=20 Amyloid Negative
- N=20 Amyloid Positive
- Age 60-80

**Protocol**

- Quantitative PET scan for amyloid burden
- Pre- and post-intervention in-clinic EVO assessments before and after drug administration
- 4 weeks at home play 5 days per week 30-45 minutes per day
- 4 weeks waitlist period

**Affiliates**

- Pfizer (Sponsor) non exclusive collaboration

**Stage**

- Project End Date 04.2016

**Affiliates**

- Pfizer (Sponsor) non exclusive collaboration

**Subjects**

- N=20 Amyloid Negative
- N=20 Amyloid Positive
- Age 60-80

**Screening visit: pre- & post-intervention assessments in attention & memory**

- Randomized: methylphenidate or placebo
- Pre- and post-intervention in-clinic EVO assessments before and after drug administration
- 4 weeks at home play 5 days per week 30-45 minutes per day
- 4 week waitlist period

**Primary Endpoint**

- The effect of cognitive metrics from Project EVO to discriminate between amyloid and amyloid - healthy elderly multi groups

**Secondary Endpoint**

- Improvement in attention, impulsivity, and memory measures between pre- and post-intervention amyloid and non-amyloid cohorts on attention and memory pre- and post-intervention

**Exploratory Endpoints**

- Effect of drug on attention and memory

**Project End Date**

04.2016

**Affiliates**

- Pfizer (Sponsor) non exclusive collaboration

**Subjects**

- N=20 Amyloid Negative
- N=20 Amyloid Positive
- Age 60-80

**Screening visit: pre- & post-intervention assessments in attention & memory**

- Randomized: methylphenidate or placebo
- Pre- and post-intervention in-clinic EVO assessments before and after drug administration
- 4 weeks at home play 5 days per week 30-45 minutes per day
- 4 week waitlist period

**Primary Endpoint**

The effect of cognitive metrics from Project EVO to discriminate between amyloid and amyloid - healthy elderly multi groups

**Secondary Endpoint**

Improvement in attention, impulsivity, and memory measures between pre- and post-intervention amyloid and non-amyloid cohorts on attention and memory pre- and post-intervention

**Exploratory Endpoints**

Effect of drug on attention and memory

**Project End Date**

04.2016
AKili’s Cognitive Monitor

- Normed databases being built
- Covers specific cognitive domains
- Language/culture independent
- Centralized on the cloud
- Quantitative data 50x per second
- Suits ultra-frequent, at-home use
- Fun, engaging, & self-adaptive
- Sensitivity

Monitor

Repeatable 7-minute sessions on any
protocol - daily, weekly, etc.

fh
Many options

Clinical data & partnerships will drive regulatory path

On path to FDA submission & clearance through CDRH
Pre-submission meetings with FDA through our clinical development process
Develop all software under medical device quality systems

Regulatory path for Akili products
<table>
<thead>
<tr>
<th>Concept of Interest Measured: Technology Attributes &amp; Gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COMMENTS</strong></td>
</tr>
<tr>
<td><strong>GAP</strong></td>
</tr>
<tr>
<td><strong>ATTRIBUTE</strong></td>
</tr>
<tr>
<td><strong>CONSIDERATION</strong></td>
</tr>
<tr>
<td><strong>APPLICATION</strong></td>
</tr>
<tr>
<td><strong>GAP</strong></td>
</tr>
<tr>
<td><strong>ATTRIBUTE</strong></td>
</tr>
<tr>
<td><strong>CONSIDERATION</strong></td>
</tr>
<tr>
<td><strong>APPLICATION</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active Programs in ADHD, Parkinson's Disease, and others</th>
<th>501k Compliant</th>
<th>Pursuing Use Case in Other Patient Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consideration</td>
<td>Met with FDA (therapy), RCT in progress</td>
<td>Audit Trial for FDA Cleared for Specific Use Case</td>
</tr>
<tr>
<td>BIometric Validation</td>
<td>Feature Prototyped and under consideration</td>
<td>Large RCT in progress for ADHD therapy</td>
</tr>
<tr>
<td>IEC 62304 – Software Verification</td>
<td>Analytical Validation</td>
<td>Clinical Validation</td>
</tr>
<tr>
<td>Time Stamp of Data Acquisition</td>
<td>User Interface Validation</td>
<td>Secure Data Transfer</td>
</tr>
</tbody>
</table>

Copyright © 2018, Akili Interactive Labs, Inc. PROPRIETARY